DRG Market Assessment reports

A series of launches are expected to continue to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market in the next 10 years and challenge the dominance of the TNF inhibitors,…

Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations in 45 countries. We report the total prevalence of HBV…

Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations in 45 countries. We report the total prevalence of HBV…

Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations in 45 countries. We report the total prevalence of HBV…

Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations in 45 countries. We report the total prevalence of HBV…

Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations in 45 countries. We report the total prevalence of HBV…

We expect the ulcerative colitis (UC) market to grow steadily over the next decade. The availability of non-TNF biologics (e.g., Takeda’s Entyvio, Janssen’s Stelara) and the first oral JAK…

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva),…

CAR T-cell therapies have given new hope to patients with relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL) and more recently to patients with R/R multiple myeloma. Priced at more than $350,…

Since the approval of the first biosimilar in Europe more than a decade ago, the adoption of biosimilars has been increasing among all specialties. The FDA approved Sandoz’s Zarxio (filgrastim)…

Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…

Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…